Copenhagen Research Center for Mental Health - CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPsych, Aarhus and Copenhagen, Denmark.
Psychol Med. 2020 Feb;50(3):499-506. doi: 10.1017/S0033291719000370. Epub 2019 Mar 18.
Previous studies have shown a potential for cannabis in disorders of the digestive organs. We aimed to investigate whether cannabis use disorders (CUD) would decrease the risk of incident disorders of the digestive organs, in people with schizophrenia and population controls.
We combined nationwide Danish registers to identify 21 066 cases with schizophrenia and 176 935 sex-and-age-matched controls. Two models were analyzed for the associations between CUD and digestive disorders in time-varying Cox regressions: one adjusted for sex, year of birth, and calendar year; and one further adjusted for alcohol and other substance use disorders and parental education.
CUD was associated with a decreased risk of developing disorders of gut-brain interaction (e.g. irritable bowel syndrome, dyspepsia, etc.) among cases with schizophrenia (HR = 0.84, 95% CI 0.74-0.94, p = 0.003). CUD was associated with decreased risk of inflammatory bowel disease (HR = 0.70, 95% CI 0.49-0.99, p = 0.045) in the basically adjusted model, dropping just below statistical significance in the fully adjusted model (HR = 0.71, 95% CI 0.48-1.03, p = 0.07). CUD displayed a tendency toward a decreased risk of serious disorders of the digestive organs among cases with schizophrenia (HR = 0.89, 95% CI 0.77-1.02, p = 0.09) in the fully adjusted model. No associations were observed among controls.
In people with schizophrenia, but not in controls, CUD is associated with decreased risk of disorders of gut-brain interaction and inflammatory bowel disease, and possibly other serious disorders of the digestive organs. Our findings could lead to new targets for treatment and prevention of disorders of the digestive organs.
先前的研究表明,大麻在消化系统疾病中具有潜在作用。我们旨在研究大麻使用障碍(CUD)是否会降低精神分裂症患者和普通人群中消化系统疾病的发病风险。
我们结合了丹麦全国范围内的登记册,以确定 21066 例精神分裂症患者和 176935 名性别和年龄匹配的对照者。我们使用时间变化的 Cox 回归分析了 CUD 与消化系统疾病之间的关联,分析了两种模型:一种调整了性别、出生年份和日历年份;另一种进一步调整了酒精和其他物质使用障碍以及父母教育。
在患有精神分裂症的患者中,CUD 与肠-脑相互作用障碍(例如肠易激综合征、消化不良等)的发病风险降低相关(HR = 0.84,95%CI 0.74-0.94,p = 0.003)。在基本调整模型中,CUD 与炎症性肠病的发病风险降低相关(HR = 0.70,95%CI 0.49-0.99,p = 0.045),在完全调整模型中则略微低于统计学意义(HR = 0.71,95%CI 0.48-1.03,p = 0.07)。在完全调整模型中,CUD 显示出降低精神分裂症患者严重消化系统疾病发病风险的趋势(HR = 0.89,95%CI 0.77-1.02,p = 0.09)。在对照组中未观察到关联。
在精神分裂症患者中,但不在对照组中,CUD 与肠-脑相互作用障碍和炎症性肠病的发病风险降低相关,并且可能与其他严重的消化系统疾病相关。我们的发现可能为治疗和预防消化系统疾病提供新的靶点。